Clinical Trial

Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II study. All patients are treatment naive extensive stage small cell lung cancer(ES-SCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of Ivonescimab and Cadonilimab in combination with chemotherapy in patients with ES-SCLC.
Trial Details
NCT Number NCT06769971
Lead Sponsor Sichuan University
Conditions Small Cell Lung Cancer
Enrollment 80 participants
Start Date 2025-02-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-10